Saturday 17 October 2026 Export MLEC’s income statement to Excel — free account

Moolec Science SA

In the quarter to December 2025, revenue grew 948.4%, EPS fell 20.0% and free cash flow grew 4.48%, each against the same quarter a year earlier.

1.68 0.19 −10.16%

Follow MLEC

Alert me

Market cap: $1.4M
P/E: 0.0×
Fwd P/E: −2.5×
Dividend yield: —
F-score: 3/9
Altman Z: −1.92
Beneish M: −7.76
Dividend safety: 0/100

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 23.05%

Capital & Financial Ratios $m

Market Cap 1.36

Revenue 468.58

Net Income 63.40

Free Cash Flow 18.34

Net Debt 65.32

Current Ratio 0.15

Debt/Equity 4.37

P/E ratio 0.00

Fwd P/E (2.54)

P/S ratio 0.00

P/B ratio 0.03

Past 5Y EPS Growth —

This Y EPS Growth (36.84%)

Next Y EPS Growth 7.69%

Next Y revenue growth (97.41%)

Next 5Y EPS Growth —

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/B against its own 10 years 0.09%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

Assets vs Liabilities $m

	2023	2024	2025	Q'25
Cash	3	68	9	1
Receivables	2	244	20	4
Inventory	0	126	2	4
Other	—	—	—	—
	5	438	31	9

	2023	2024	2025	Q'25
Payables	7	169	7	7
ST’ Debt	3	235	227	54
Other	3	5	1	0
	13	427	236	62

Compound Annual Growth %

	10y	5y	3y
Sales	—	—	617.02%
Cash Flow	—	0.00%	0.00%
Earnings	—	0.00%	0.00%
Book Value	—	0.00%	0.00%

Revenue $m

	Sep	Dec	Mar	Jun	Year
’26	—	—	—	—	—
’25	2	3	—	—	334
’24	2	0	2	462	466

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Sep	Dec	Mar	Jun	Year
’26	—	(1)	—	—	—
’25	(1)	(1)	—	—	4
’24	(2)	(4)	(3)	48	40
’23	0	(1)	(4)	(3)	(8)
’22	—	—	(1)	0	(2)
’21	(1)	0	(1)	0	(1)
’20	—	0	—	—	0

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Sep	Dec	Mar	Jun	Year
’26	—	(3)	—	—	—
’25	(1)	(1)	—	—	(11)
’24	(2)	(4)	(3)	23	15
’23	—	—	(4)	(3)	(8)
’23	0	(1)	—	—	(8)
’22	—	—	(1)	0	(2)
’21	(1)	0	(1)	0	(1)

Fiscal quarters ending in the months shown.

EPS $

	Sep	Dec	Mar	Jun	Year
’26	—	—	—	—	—
’25	(7.50)	(9.00)	—	—	(409.76)
’24	(6.00)	(7.50)	(6.00)	(55.89)	(74.84)
’23	(3.49)	(231.41)	(1.42)	11.04	(224.89)
’22	—	—	(5.64)	0.00	(21.89)
’21	36.46	—	45.41	(0.11)	(3.96)
’20	0.00	0.00	—	—	(0.67)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	—	—	—	—	—	1,432.50	1,200.00	321.00	112.50	3.08	Analyst estimates 2026–2028 Powerpack
	High	—	—	—	—	—	1,489.50	6,337.50	3,330.00	487.50	157.05
People
People	Employees	—	—	—	—	4	4	—	45	52	103
	Revenue/emp, $m	—	—	—	—	0.00	0.00	—	0.02	8.97	3.24
Income, $m
Income, $m	Revenue	—	—	—	—	—	—	—	1	466	334
	Gross margin, %	—	—	—	—	—	—	—	(15.83)	40.10	39.02
	EBT	—	—	—	—	0	0	(5)	(52)	(28)	(170)
	EBT margin, %	—	—	—	—	0.00	0.00	0.00	(5,748.44)	(5.99)	(50.96)
	Net income	—	0	—	—	0	0	(5)	(52)	(29)	(177)
	Depreciation	—	—	—	—	0	—	0	0	18	17
Per share, $
Per share, $	Revenue	—	—	—	—	0.00	0.00	0.00	3.94	1,201.07	773.86
	Earnings	—	—	—	—	(0.67)	(3.96)	(21.89)	(224.89)	(74.84)	(425.39)
	Cash flow	—	—	—	—	(0.43)	(38.61)	(9.12)	(32.67)	101.87	8.44
	Capex	—	—	—	—	0.00	0.00	0.00	(0.78)	(63.58)	(33.00)
	Free cash flow	—	—	—	—	(0.43)	(38.61)	(9.12)	(33.45)	38.29	(24.57)
	Book value	—	—	—	—	0.60	(132.67)	7.76	43.96	643.84	(192.24)
	Shares, m	—	—	—	—	0	0	0	0	0	0
Valuation, ×
Valuation, ×	P/E	—	—	—	—	—	—	—	0.00	0.00	0.00
	P/S	—	—	—	—	—	—	—	0.00	0.14	0.05
	P/B	—	—	—	—	—	—	—	12.56	0.26	8.78
	EV/Sales	—	—	—	—	—	—	—	0.00	0.96	0.10
	EV/FCF	—	—	—	—	—	—	—	(16.87)	30.45	2.46
Cash, $m
Cash, $m	Operating cash flow	—	—	—	—	0	(1)	(2)	(8)	40	4
	Capex	—	—	—	—	0	—	—	0	(25)	(14)
	Free cash flow	—	—	—	—	0	(1)	(2)	(8)	15	(11)
Balance, $m
Balance, $m	Working capital	—	—	—	—	0	(1)	(3)	(7)	11	(205)
	Total debt	—	—	—	—	0	0	—	3	451	247
	Net debt	—	—	—	—	0	0	(1)	0	383	238
	Shareholders’ equity	—	—	—	—	0	(3)	2	10	250	(83)
Returns, %
Returns, %	ROA	—	—	—	—	(4.46)	(0.14)	(6.29)	(348.24)	(6.71)	(19.31)
	ROIC	—	—	—	—	(6.57)	0.00	(436.89)	(41.93)	1.90	(42.03)
	ROE	—	—	—	—	(111.29)	5.99	587.91	(884.51)	(25.13)	(133.38)

Negative figures in brackets.

All 10 years →

Fiscal years to Jun 2025 · latest quarter Dec 2024

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
NEXI NexImmune, Inc.	$1.6M	— (loss-making)	—	—	n/m	+66.38% (above 0%: growing)	0.00%	0.00%	Compare
ITRMF Iterum Therapeutics PLC	$1.6M	— (loss-making)	— (loss-making)	+110.81% (above 0%: growing)	n/m	−179.15% (below 0%: shrinking)	94.87%	(1,982.31%)	Compare
CARM Carisma Therapeutics Inc.	$1.5M	— (loss-making)	— (loss-making)	+392.01% (above 0%: growing)	n/m	+114.65% (above 0%: growing)	100.00%	96.83%	Compare
ARTL Artelo Biosciences, Inc.	$1.5M	— (loss-making)	—	—	n/m	−879.18% (below 0%: shrinking)	0.00%	0.00%	Compare
ABPO Abpro Holdings Inc.	$1.4M	0.2×	—	—	n/m	−0.48% (below 0%: shrinking)	100.00%	0.00%	Compare
MLEC Moolec Science SA	$1.4M	— (loss-making)	— (loss-making)	+948.39% (above 0%: growing)	n/m	+4.48% (above 0%: growing)	(25.52%)	(77.92%)
PTIX Atrinsic Inc.	$1.3M	0.3×	—	+34.31% (above 0%: growing)	n/m	+46.07% (above 0%: growing)	0.00%	0.00%	Compare
SPRC SciSparc Ltd.	$1.2M	— (loss-making)	7.9×	—	n/m	+14.95% (above 0%: growing)	35.75%	0.00%	Compare
CYTOF Altamira Therapeutics Ltd.	$1.1M	— (loss-making)	— (loss-making)	—	n/m	+85.35% (above 0%: growing)	(157.79%)	0.00%	Compare
Median of peers	$1.5M	—	—	+110.81%	—	+30.51%	17.88%	0.00%

All 614 Biotechnology stocks →

Moolec Science SA (MLEC) key facts

Moolec Science SA (MLEC) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, MLEC traded at $1.68, a market capitalization of $1.4 million.
Return on equity was −133.4% and debt-to-equity 4.37.
Its Piotroski F-score is 3 out of 9 and its Altman Z-score is −1.92 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.